RMTI Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Net Sales: $17.3 million, an 8% decrease compared to Q1 2025, but exceeded expectations for the quarter.
Gross Profit: $2.9 million, consistent with Q1 2025.
Gross Margin: 17%, improved from 15% in Q1 2025, indicating enhanced manufacturing efficiency.
Net Loss: $1.6 million, slightly higher than the net loss of $1.5 million in Q1 2025.
Adjusted EBITDA: Negative $300,000, an improvement from negative $400,000 in Q1 2025.
Cash Position: $23.9 million, down from $25 million at year-end, influenced by seasonal expenses and a $500,000 payment related to the Evoqua acquisition.

2. Strategic Updates and Business Highlights

Rockwell Medical is now the primary supplier of liquid bicarbonate in the U.S., with a diverse customer base of approximately 300 clients across 1,400 facilities.
The company is implementing operational changes to enhance manufacturing and distribution efficiencies, including activating two new automated liquid lines expected to increase output by 50%.
New customer acquisitions and contract renewals with existing clients have improved pricing and product mix.
The company is focused on expanding its portfolio of renal care products and enhancing treatment options for patients.

3. Forward Guidance and Outlook

2026 Annual Guidance:
- Net sales projected between $70 million and $75 million.
- Gross margin expected to range from 18% to 22%.
- Anticipated adjusted EBITDA of $1 million to $2 million.
- Positive operating cash flow expected, eliminating the need for additional capital raises.
Long-term goals include achieving annual net sales above $100 million by 2029, with gross margins potentially approaching 30%.

4. Bad News, Challenges, or Points of Concern

The decrease in net sales year-over-year was attributed to declining volumes from the company’s largest customers.
The net loss increased slightly, indicating ongoing challenges in achieving profitability.
Seasonal expenses historically impact Q1 results, leading to negative adjusted EBITDA.
The company is navigating competitive pressures and market dynamics that could affect growth and profitability.

5. Notable Q&A Insights

Rockwell Medical is seeing strong demand for products outside the U.S., particularly in Latin America, with higher margins due to distributor-led sales.
The company is successfully onboarding new customers in the West and is establishing a distribution presence in that region.
Pricing adjustments are being made across both new and existing customers, with no reported pushback on these changes.
Ongoing negotiations with DaVita, a key customer, remain positive, with indications of continued collaboration and a recent large purchase from them.

Overall, Rockwell Medical is focused on improving operational efficiencies, expanding its customer base, and achieving profitability while facing some challenges related to customer volume and seasonal expenses.

RMTI — Rockwell Medical, Inc.